<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>IGAN.knit</title>

<script src="site_libs/header-attrs-2.22/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>







<link rel="stylesheet" href="styles.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}

.tocify-subheader {
  display: inline;
}
.tocify-subheader .tocify-item {
  font-size: 0.95em;
}

</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Renal Medicine</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Research
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./trials.html">Trials</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GEN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HTN.html">HTN</a>
    </li>
    <li>
      <a href="./CCF.html">CCF</a>
    </li>
    <li>
      <a href="./DKD.html">DKD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    U&amp;E
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./acidbase.html">H+ &amp; HCO3</a>
    </li>
    <li>
      <a href="./na.html">Na</a>
    </li>
    <li>
      <a href="./k.html">K</a>
    </li>
    <li>
      <a href="./mg.html">MG</a>
    </li>
    <li>
      <a href="./renalbone.html">Ca2+ &amp; PO4</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    GN
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./MCD.html">MCD</a>
    </li>
    <li>
      <a href="./ANCA.html">ANCA</a>
    </li>
    <li>
      <a href="./IGAN.html">IGAN</a>
    </li>
    <li>
      <a href="./MPGN_C3G.html">MPGN &amp; C3G</a>
    </li>
    <li>
      <a href="./LUPUS.html">LUPUS</a>
    </li>
    <li>
      <a href="./FSGS.html">FSGS</a>
    </li>
    <li>
      <a href="./TMA.html">TMA</a>
    </li>
    <li>
      <a href="./GBM.html">GBM</a>
    </li>
    <li>
      <a href="./MN.html">MN</a>
    </li>
    <li>
      <a href="./Amyloid.html">Amyloid</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    CKD
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Checklist</a>
    </li>
    <li>
      <a href="./project1.html">Conservative care</a>
    </li>
    <li>
      <a href="./anaemia.html">Anaemia</a>
    </li>
    <li>
      <a href="./project1.html">Pruritis</a>
    </li>
    <li>
      <a href="./renalbone.html">CKD-MBD</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    TX
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./project1.html">Cheat sheet</a>
    </li>
    <li>
      <a href="./txnotes.html">Misc Notes</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    RRT
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./HD.html">HD</a>
    </li>
    <li>
      <a href="./project1.html">Home HD</a>
    </li>
    <li>
      <a href="./project1.html">HD Access</a>
    </li>
    <li>
      <a href="./project1.html">PD</a>
    </li>
    <li>
      <a href="./project1.html">CVVH</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    DRUGS
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./anticoagulation.html">Anticoagulation</a>
    </li>
    <li>
      <a href="./PJP.html">PJP</a>
    </li>
    <li>
      <a href="./abx.html">Abx</a>
    </li>
    <li>
      <a href="./aboutme.html">HDU</a>
    </li>
    <li>
      <a href="./project1.html">Flozins</a>
    </li>
    <li>
      <a href="./rituxcyc.html">RITUX &amp; CYC</a>
    </li>
    <li>
      <a href="./Chemotherapy.html">Chemo</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    MISC
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./biopsy.html">Biopsy</a>
    </li>
    <li>
      <a href="./path.html">PATH</a>
    </li>
    <li>
      <a href="./preg.html">Pregnancy</a>
    </li>
    <li>
      <a href="./project1.html">PEX</a>
    </li>
    <li>
      <a href="./Lymphoproliferative.html">Lymphoproliferative</a>
    </li>
    <li>
      <a href="./covid19.html">SARS-Cov-2</a>
    </li>
    <li>
      <a href="./Tumour_Lysis.html">Tumour Lysis Syndrome</a>
    </li>
    <li>
      <a href="./Single Kidney.html">Single Kidney</a>
    </li>
    <li>
      <a href="./IGG4.html">IGG4</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Resources
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="./edu.html">Educational Resources</a>
    </li>
    <li>
      <a href="./patient_resources.html">Patient Resources</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https:eoindosullivan.com">
    <span class="fas fa-home"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">




</div>


<div id="igan" class="section level1">
<h1>IgAN</h1>
<ul>
<li>Most common type of glomerulonephritis</li>
<li>1.5 of 100,000 individuals per year</li>
<li>2:1 M:F in North America, 1:1 in Asia</li>
<li>1-3% of all cases of end stage kidney disease</li>
<li>The prevalence is highest in Asian countries - 30% of all kidney
biopsies (and 45% of glomerulonephritis cases) cultural biopsy practice
a factor?</li>
<li>5% of biopsies in the United States and Europe.</li>
<li>Classic presentation: microscopic hematuria, asympomatic, picked up
on screening</li>
<li>Atypical &amp; Non-Specific presentations can be tricky: abdominal
pain, hypertension, and proteinuria.</li>
<li>HSP spectrum</li>
<li>Large variability in outcomes:
<ul>
<li>10-year risk of ESKD ~ 30-40% worldwide</li>
<li>10 year risk of ESKD ~ 10% if normal eGFR at presentation</li>
<li>Risk prediction important, see below.</li>
</ul></li>
</ul>
<div id="secondary-iga" class="section level3">
<h3>Secondary IgA</h3>
<ul>
<li><pre><code>IBD, Coelic, cirhossis, chronic infection (HIV), some malignancies</code></pre></li>
</ul>
</div>
</div>
<div id="pathology" class="section level1">
<h1>Pathology</h1>
<ul>
<li>Abnormal glycosylation of IgA</li>
<li>Abnormal IgA is galactose-deficient and consequently recognized by
anti-glycan IgG or IgA1 antibodies</li>
<li>These immune complexes deposit in mesangium causing injury</li>
</ul>
</div>
<div id="risk-stratification" class="section level1">
<h1>Risk Stratification</h1>
<p><strong>Established risk factors</strong></p>
<ul>
<li>Male sex</li>
<li>Proteinuria &gt;1 g/d</li>
<li>Hypertension</li>
<li>Reduced GFR</li>
<li>Hyperuricemia</li>
</ul>
<p><a href="https://www.nejm.org/doi/full/10.1056/NEJMra1206793">Back of
the Envelope method</a></p>
<p>Consider:</p>
<ul>
<li>Proteinuria &gt; 1 g per day</li>
<li>HTN (&gt;140/90 mm Hg)</li>
<li>“severe” histologic lesions on the basis of glomerular, vascular,
tubular, and interstitial features.</li>
</ul>
<p>20-year survival without RRT = 96% if no risk factors 36% with 3.</p>
<p><strong>Histological methods</strong></p>
<div id="mest-c" class="section level2">
<h2>MEST-C</h2>
<p><em>Useful for research but less useful for clinical
decisions</em></p>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/27612994/">MEST-C scoring -
The Oxford Study</a></p>
<ul>
<li><strong>M</strong>esangial hypercellularity; diffuse, involving
greater than 50% of glomeruli</li>
<li><strong>E</strong>ndocapillary hypercellularity: any, even if
limited to a single loop of a single glomerulus</li>
<li><strong>S</strong>egmental sclerosis: any</li>
<li><strong>T</strong>ubular atrophy and interstitial fibrosis: 25-50%
cortex, &gt;50% of cortex</li>
</ul>
<p>Mesangial hypercellularity, endocapillary hypercellularity, and
crescent formation are histopathologic indicators of activity, while
segmental sclerosis and tubular atrophy indicate chronicity. E is
worst.</p>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/27612994/">Crescents added
in 2019</a></p>
<ul>
<li>C0 (no crescents)</li>
<li>C1 (crescents &lt; 25% gloms), identifying patients at increased
risk of poor outcome without immunosuppression</li>
<li>C2 (crescents &gt;25% gloms), identifying patients at even greater
risk of progression, even with immunosuppression</li>
<li>Fibrous (&lt;10% cells and ≥90% matrix) crescents don’t count
(fibrocellular are ok)</li>
</ul>
<p>If you are C2, HRs for a (composite outcome of either ESRD or ≥50%
reduction in eGFR; increased rate of eGFR decline) was of 3.26 (95% CI,
1.47 to 7.34; P=0.004) in untreated and and 2.43 (95% CI, 1.17 to 5.06)
if treated with Immunosuppression. Not particularly different!</p>
<p>M, S crescents enhance ability to predict outcomes only in patients
who had not received immunosupression. <a
href="http://www.nephjc.com/news/2016/10/16/do-crescents-matter-for-iga-nephropathy">Nice
NephJC</a></p>
</div>
<div id="valiga" class="section level2">
<h2>VALIGA</h2>
<p><a
href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184028/">VALIGA</a></p>
<p><em>European validation of Oxford study</em></p>
<ul>
<li>1147 patients | 13 European countries | median follow-up of 4.7
years</li>
<li>86% ACEi/ARB, 42% steroids/IS</li>
</ul>
<p>MST = predict loss of renal function</p>
<p>If eGFR &lt;30, MT = predict loss of renal function</p>
<p>If Proteinuria &lt;0.5/day, ME = predict rise in proteinuria to
1-2g/day</p>
<p>As with Oxford, MST enhance ability to predict outcomes only in
patients who had not received immunosupression</p>
</div>
<div id="prediction-models" class="section level2">
<h2>Prediction models</h2>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/30980653/">International IgA
Nephropathy Network Prediction models</a></p>
<p>Parameters:</p>
<ul>
<li>Age</li>
<li>Ethnicity</li>
<li>Blood pressure</li>
<li>GFR</li>
<li>Proteinuria</li>
<li>Use of renin-angiotensin system blockade</li>
<li>Use of immunosuppression</li>
<li>Pathologic variables (MEST-score)</li>
</ul>
<p><strong>Generalizability</strong></p>
<ul>
<li><p>Adult patients, no pediatric patients.</p></li>
<li><p>White, Chinese and Japanese patients only</p></li>
<li><p>Biopsy-proven IgA nephropathy only so the full models cannot be
applied in patients who have not undergone biopsy.</p></li>
<li><p>Needs to be applied at the time of bx only</p></li>
<li><p>Not appropriate for Rx decisions</p></li>
</ul>
<p><a
href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults">Calculator
here</a></p>
<p><strong>GWAS</strong></p>
<p><a
href="https://journals.plos.org/plosgenetics/article?id=10.1371%2Fjournal.pgen.1002765">IgA
GWAS</a></p>
<p>Risk genes increase as you move West to East but ultimately only
explain ~7% of overall risk.</p>
<p>Interesting implications for variable of “Race” in data and what it
really is capturing – at times, these risk genes, but also captures
range of diverse and ill-defined cultural/socioeconomic patterns.</p>
<p>Not entirely clear what relationship “race” has to IGAN, possibly
worse outcomes in “Chinese” populations but unclear if that applies to
Chinese Nationals of those with Chinese heritage in other countries. No
evidence of differential treatment effects.</p>
</div>
</div>
<div id="treatment" class="section level1">
<h1>Treatment</h1>
<ul>
<li><p>If proteinuria, optimise long term ACE-i/ARB to max
tolerated</p></li>
<li><p>Threshold for starting per KDIGO &gt;1g/d</p></li>
<li><p>BP &lt;130/80</p></li>
</ul>
<div id="stop-igan" class="section level2">
<h2>STOP-IgAN</h2>
<p><a
href="https://www.nejm.org/doi/full/10.1056/NEJMoa1415463">STOP-IgAN</a></p>
<p><em>Heavy Immunosuppression for moderate IgA disease</em></p>
<p><strong>Inclusion:</strong></p>
<p>Bx confirmed IGAN, aged 18-70, proteinuria &gt;0.75g/d &amp; HTN,
eGFR&lt;90</p>
<p><strong>Excluded:</strong></p>
<p>Secondary IGAN, rapid progression/crescents, previous
immunosuppression</p>
<p><strong>Endpoint:</strong></p>
<ul>
<li>Decrease in eGFR of 15 or remission (Pro/24hrs &lt;0.2, eGFR decline
&lt;5)</li>
</ul>
<p>6 months run in to optimise | <strong>N</strong>= (337) -&gt;177
randomised over 3 years</p>
<p><strong>The immunosuppression</strong></p>
<ul>
<li>eGFR &gt;59 received 1g of IV methylprednisolone daily for 3 days at
the start of months 1, 3 and 5; and oral prednisolone at a dose of 0.5
mg/kg every other day</li>
<li>eGFR 30-59 received cyclophosphamide 1.5 mg/kg/day for 3 months,
followed by azathioprine at a dose of 1.5 mg/kg per day during months
4-36, plus oral prednisolone 40 mg/day, tapered to 10 mg/day, over the
first 3 months of the study, 10 mg/day during months 4-6 and 7.5 mg per
day during months 7-36.</li>
</ul>
<p><strong>Results</strong></p>
<p>Immunosuppression led to</p>
<ul>
<li>More remission (14 vs 4) OR 4.82 (1.43-16.30)</li>
<li>No change in eGFR decline of at least 15 (22 vs 21) OR 0.89
(0.41-1.90)</li>
</ul>
<p><strong>Conclusion</strong></p>
<ul>
<li>Probably not super useful in these patients (? Takes longer to
demonstrate eGFR improvement?)</li>
<li>Doesn’t apply to heavy proteinuria &lt;35g or rapid
progression/crescents who probably need immunosuppression</li>
<li>34% of patients had &lt;0.75g proteinuria per day at six<br />
months, with supportive care alone. Get them on ACEi</li>
</ul>
</div>
<div id="testing" class="section level2">
<h2>TESTING</h2>
<p><a
href="https://jamanetwork.com/journals/jama/article-abstract/2792252">TESTING</a></p>
<p><em>Steroids in IgAN: the one that was reimagined half way through
due to safety concerns</em></p>
<p><strong>Inclusion:</strong></p>
<p>Patients with IGAN &gt;= 1g proteinuria/day, 12 week run in
ACEi/ARB</p>
<p><strong>Excluded:</strong></p>
<p>Secondary IGAN, MCD, &gt;50% crescents, infection, cancer</p>
<p><strong>Endpoint:</strong></p>
<p>40% decreased in eGFR/ESKD/death | ESKD | Death</p>
<p><strong>The immunosuppression regime:</strong></p>
<p><strong>High dose:</strong> 0.6-0.8 mg/kg/d, maximum 48 mg/d, weaning
by 8 mg/d/mo; n = 136</p>
<p><strong>Low dose Regime:</strong> (0.4 mg/kg/day, maximum 32 mg/day)
for 2 months, followed by weaning by 4 mg/day/month over 6-9 months, or
matching placebo.</p>
<p>&amp; PJP prophylaxis for 12 weeks (cotrim)</p>
<p><strong>Results</strong></p>
<ul>
<li>N=503, 5 countries | mean age 38 | mean eGFR, 61.5 | mean
proteinuria, 2.46 g/d | 98% completed trial</li>
<li>Chinese heritage well represented ~ 75% (initial funding &amp;
recruitment in China/oz)</li>
<li>60:40 M:F</li>
<li>Methylpred full-dose HR, 0.58 (95% CI, 0.41-0.81); reduced-dose HR,
0.27 (95% CI, 0.11-0.65)</li>
<li>SAE were higher in pred obviously, but almost entirely in the high
dose infections</li>
<li>Proteinuria rebound after initial dip but eGFR maintains benefit -
legacy effect?</li>
</ul>
<p><strong>Conclusion:</strong></p>
<p>Probably low dose is reasonable in high risk of progression, single
regime, I wouldn’t repeat if later “flare” or retreat unless they were
exceptionally tolerant of initial regime and rebiopsy showed activity
and minimal sclerosis</p>
<p><strong>Notes:</strong></p>
<p>E1, E0 both responded to treatment, despite previous suggestions from
MEST 2009</p>
<p>Effect was not exclusive to Chinese (questions around Stop IgA
suggested their European centres were the reason for lack of efficacy –
this appears not to be the case)</p>
<p>By the end of trial, initial drop in proteinuria has returned to
baseline</p>
<ul>
<li>In international cohorts there is a benefit in inducing remission
with diminishing returns on duration ending around 3-4 years –
i.e. There appears to be a legacy benefit to long term outcomes based on
initial proteinuria reduction in international cohorts</li>
<li>In clinic, a rising proteinuria probably indicates sclerosis /
conversion to DAPA-CKD like phenotype / could be a flare but who knows
what to do with that. Prob not immunosuppress anyway</li>
</ul>
</div>
<div id="nefigan" class="section level2">
<h2>NEFIGAN</h2>
<p><a
href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30550-0/fulltext">NEFIGAN</a></p>
<p><em>Oral, enteric coated Budesonide in IgA</em></p>
<p>Oral option, USA has enteric coated on patent (100k/9 months in
US!)</p>
<p>Has less side effects due to first pass metabolism</p>
<p>Evidence that proteinuria reduction in phase 2, but ongoing phase 3
trials to correlate with longer term eGFR changes.</p>
</div>
<div id="protect" class="section level2">
<h2>PROTECT</h2>
<p><a
href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext">PROTECT</a></p>
<p><em>Sparsentan in IgA - prespecified interim analysis</em></p>
<p>Biopsy proven IGAN with &gt;1g proteinuria /day.</p>
<p>Sparsentan 400mg vs Irbesartan 300mg</p>
<p>Primary Endpoint: Change from baseline to week 36 uPCR</p>
<p>At week 36, the geometric least squares mean percent change from
baseline in urine protein–creatinine ratio was statistically
significantly greater in the sparsentan group (–49·8%) than the
irbesartan group (–15·1%), resulting in a between-group relative
reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51–0·69;
p&lt;0·0001)</p>
</div>
<div id="sglt2i-in-iga" class="section level2">
<h2>SGLT2i in IgA</h2>
<ul>
<li>TESTING are patients in their 30s, heavy proteinuria (2.5g), eGFR in
60s.</li>
<li>STOP IgA, Proteinuria 1.5g/day (pre-MEST) – more scarred and less
active bx (a lot of S1 on subsequent reanalysis of bx)</li>
<li>In contrast <a
href="https://www.nejm.org/doi/full/10.1056/NEJMoa2024816">DAPA-CKD
subgroup with IgA</a> – 10 years older, 20mls less eGFR, proteinuria
&lt;1g/day (i.e.? burning out/scarred? very small subgroup, only 26
events in subgroup) – Placebo risk of primary outcome ~18% @ 2 years. To
get this level of risk given low proteinuria – must have lots of T2
lesions and scarring.</li>
<li>Probably most appropriate to use a SGLT2i to somebody who
<em>isn’t</em> a candidate for immunosuppression, want to augment
conservative therapy</li>
<li>Immunosuppressive options in early phase | Flozins for burning out
disease</li>
<li>Potential downsides: Steroids &amp; SGLT2i -? infection risk, might
mask proteinuria and confuse treatment decisions.</li>
</ul>
</div>
</div>
<div id="iga-vasculitis" class="section level1">
<h1>IgA Vasculitis</h1>
<p><em>The artist formally known as HSP</em></p>
<ul>
<li>Skin – 95%
<ul>
<li>a petechial or purpuric rash in dependent areas (typically the
buttocks and lower legs)</li>
<li>bullae</li>
<li>oedema</li>
<li>necrosis</li>
<li>In infants, the rash may be limited to the arms or face</li>
<li>BX: leukocytoclastic vasculitis with IgA deposition in the
vessels.</li>
</ul></li>
<li>Gastrointestinal tract - 70%</li>
<li>Joints – 70-90%</li>
<li>Large joints in legs, appearing late in about 6% ( &gt;a week post
dx) – usually no chronic sequelae</li>
<li>Kidneys 40-50%, possibly more as microhematuria present in the
majority of patients.
<ul>
<li>Identical histology to IgAN</li>
<li>25% microscopic haematirua</li>
<li>Mild proteinuria 15%</li>
<li>CKD develops in 1-2%</li>
<li>Monitor Cr and BP for 6 months post dx</li>
<li>CKD can develop late, notably during pregnancy</li>
</ul></li>
<li>Orchitis (in 14% of male patients)</li>
<li>central nervous system involvement rare</li>
</ul>
<div id="diagnosis" class="section level3">
<h3>Diagnosis</h3>
<ul>
<li><p>Diagnosis of IgA vasculitis is clinical, but in cases in which
there is diagnostic uncertainty, it can be confirmed by biopsy of an
affected organ.</p></li>
<li><p>International consensus guidelines require the presence of
palpable purpura in addition to abdominal pain, arthritis or arthralgia,
renal involvement, or compatible histopathologic evidence.</p></li>
<li><p>Elevated IgA levels are neither necessary nor sufficient for
diagnosis</p></li>
<li><p>Type III immune complex diseases such as IgA vasculitis are
complement-mediated, plasma complement levels are usually
normal.</p></li>
</ul>
</div>
<div id="management" class="section level3">
<h3>Management</h3>
<ul>
<li><p>IgA vasculitis is primarily managed with supportive care and
monitoring for complications. IgA vasculitis is generally self-limited,
with complete resolution of symptoms and no long-term sequelae in the
vast majority of cases.</p></li>
<li><p>Glucocorticoids are indicated for severe symptoms, especially
those involving the gastrointestinal or musculoskeletal
systems.</p></li>
<li><p>A systematic review including mostly retrospective studies and
three randomized, placebo-controlled trials showed that glucocorticoids
increased the odds of resolution of abdominal pain within 24 hours and
suggested renal benefits.</p></li>
<li><p>However, the largest randomized trial involving patients with IgA
vasculitis showed no evidence that glucocorticoids prevented the
development of nephropathy.</p></li>
</ul>
</div>
</div>
<div id="misc" class="section level1">
<h1>MISC</h1>
<ul>
<li>19% recurrance in Tx at 10 years</li>
<li>23% at 15 years</li>
</ul>
<div id="tips" class="section level2">
<h2>Tips</h2>
<ul>
<li>The main discriminator between IGAN and IGAV are the cutaneous
petechiae or palpable purpura seen only in IgAV.Biopsy is not reliable
way to distinguish.</li>
</ul>
</div>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = false;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
